Immune System Interactions in Pancreatic Cancer

A Comprehensive Overview of the Tumor Microenvironment

Abstract

The immune system plays a paradoxical role in pancreatic cancer, simultaneously promoting anti-tumor immunity and creating an immunosuppressive microenvironment that facilitates tumor growth and metastasis. Understanding these complex interactions between various immune cell populations and tumor cells is critical for developing effective immunotherapeutic strategies. This document provides a comprehensive analysis of the key immune components within the pancreatic tumor microenvironment, including macrophages, myeloid-derived suppressor cells (MDSCs), natural killer (NK) cells, dendritic cells, and neutrophils, exploring their dual roles in both tumor suppression and progression.

Introduction

Pancreatic cancer represents one of the most challenging malignancies in oncology, characterized by poor prognosis and limited therapeutic options. The pancreatic tumor microenvironment is notably complex, featuring extensive desmoplasia, hypoxia, and profound immunosuppression. Within this hostile landscape, multiple immune cell populations interact dynamically with tumor cells, stromal elements, and each other, creating a network of regulatory mechanisms that profoundly influence disease progression.

Recent advances in immunology have revealed that these immune cells exhibit remarkable plasticity, capable of adopting pro-tumor or anti-tumor phenotypes depending on local environmental cues. This functional diversity presents both challenges and opportunities for therapeutic intervention, as targeting specific immune populations or modulating their activation states may shift the balance toward effective anti-tumor immunity.

Overview of Immune Cell Interactions



Figure 1. Schematic representation of immune system interactions in the pancreatic tumor microenvironment, illustrating the complex network of immune cell types and their regulatory pathways.

Key Immune Cell Populations

Macrophages: Dual Regulators of Tumor Immunity

Macrophages represent one of the most abundant immune cell populations in the pancreatic tumor microenvironment and serve as critical regulators of tumor progression. These highly plastic cells can polarize into functionally distinct phenotypes, broadly classified as M1 (classically activated) and M2 (alternatively activated) macrophages, each exerting opposing effects on tumor immunity.

M1 Macrophages: Pro-Inflammatory Anti-Tumor Effectors

M1 macrophages are typically activated by interferon-gamma (IFN-γ) and lipopolysaccharide (LPS), adopting a pro-inflammatory phenotype

characterized by the production of reactive oxygen species (ROS), nitric oxide (NO), and pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-1β (IL-1β), and IL-12. These cells possess potent tumoricidal activity through both direct cytotoxic mechanisms and the recruitment and activation of other anti-tumor immune effectors, including cytotoxic T lymphocytes (CTLs) and NK cells.

M1 macrophages also function as efficient antigen-presenting cells, expressing high levels of MHC class II molecules and co-stimulatory molecules such as CD80 and CD86, thereby facilitating T cell activation and adaptive anti-tumor immune responses.

M2 Macrophages: Immunosuppressive Tumor Promoters

In stark contrast, M2 macrophages promote tumor growth, angiogenesis, tissue remodeling, and immunosuppression. These cells are typically activated by IL-4, IL-10, IL-13, and transforming growth factor-beta (TGF-β), and are abundantly present in pancreatic tumors, often referred to as tumor-associated macrophages (TAMs).

M2 macrophages secrete a distinct repertoire of immunosuppressive factors:

- Interleukin-10 (IL-10): Potently suppresses T cell activation and dendritic cell maturation
- Transforming Growth Factor-Beta (TGF-β): Inhibits cytotoxic T lymphocyte function and promotes regulatory T cell (Treg) expansion
- CTLA-4: Expressed on macrophage surfaces, this checkpoint molecule directly inhibits T cell activation through engagement with CD80/CD86 on antigen-presenting cells

Furthermore, M2 macrophages produce matrix metalloproteinases (MMPs) and vascular endothelial growth factor (VEGF), facilitating tumor invasion, metastasis, and angiogenesis. The predominance of M2-polarized macrophages in pancreatic cancer correlates with poor prognosis and resistance to conventional therapies.

Myeloid-Derived Suppressor Cells (MDSCs): Architects of Immune Evasion

Myeloid-derived suppressor cells represent a heterogeneous population of immature myeloid cells that accumulate preferentially in tumor-bearing hosts. In pancreatic cancer, MDSCs constitute a major component of the immunosuppressive tumor microenvironment, actively suppressing anti-tumor immune responses through multiple mechanisms.

MDSC Subtypes and Phenotypic Characteristics

MDSCs are broadly classified into two major subtypes based on morphology and surface marker expression:

- Monocytic MDSCs (M-MDSCs): Morphologically similar to monocytes, these cells express high levels of CD14 in humans and Ly6C in mice. M-MDSCs primarily suppress immune responses through the production of immunosuppressive cytokines and reactive nitrogen species.
- Polymorphonuclear MDSCs (PMN-MDSCs): Resembling neutrophils in appearance, these cells are characterized by high expression of CD15 and CD66b in humans, and Ly6G in mice. PMN-MDSCs exert immunosuppression predominantly through arginase-1 (ARG1) activity and reactive oxygen species (ROS) production.

Mechanisms of MDSC-Mediated Immunosuppression

MDSCs employ diverse molecular mechanisms to suppress T cell activation and proliferation:

- Arginine depletion: MDSCs express high levels of arginase-1 and inducible nitric oxide synthase (iNOS), which metabolize L-arginine, an amino acid essential for T cell receptor signaling and proliferation. Arginine depletion results in T cell cycle arrest and anergy.
- Reactive oxygen and nitrogen species: MDSCs produce high levels of ROS and reactive nitrogen species (RNS), which modify the T cell receptor complex and impair antigen recognition, while also inducing T cell apoptosis.
- Checkpoint molecule expression: MDSCs express PD-L1 (programmed death-ligand 1), which engages PD-1 on T cells, delivering inhibitory signals that suppress T cell function and promote exhaustion.
- Regulatory T cell expansion: MDSCs promote the differentiation and expansion of immunosuppressive regulatory T cells (Tregs) through secretion of IL-10 and TGF-β, further dampening anti-tumor immunity.

Natural Killer (NK) Cells: Frontline Innate Immune Effectors

Natural killer cells constitute a critical component of the innate immune system, capable of recognizing and eliminating malignant cells without prior sensitization. Unlike T cells, which require MHC-mediated antigen presentation, NK cells detect stressed or transformed cells through an intricate balance of activating and inhibitory receptor signals.

NK Cell Activating Receptors and Ligands

NK cell activation is mediated by several families of activating receptors that recognize stress-induced ligands on tumor cells:

- CD16 (FcγRIII): Mediates antibody-dependent cellular cytotoxicity (ADCC) by binding the Fc region of IgG antibodies coating target cells, enabling NK cells to destroy antibody-opsonized tumor cells.
- Natural Cytotoxicity Receptors (NCRs): Including NKp30, NKp44, and NKp46, these receptors recognize ligands upregulated on stressed or transformed cells, directly triggering NK cell degranulation and target cell lysis.
- DNAM-1 (CD226): Binds to CD155 (PVR) and CD112 (nectin-2), which are frequently overexpressed on tumor cells, promoting NK cell adhesion, cytokine production, and cytotoxicity.
- NKG2D: Recognizes stress-induced ligands such as MICA, MICB, and ULBPs, which are upregulated in response to DNA damage, cellular stress, or viral infection, providing a critical activating signal for NK cell-mediated tumor cell killing.

Cytokine-Mediated NK Cell Activation

NK cell function is profoundly influenced by the local cytokine milieu. Several cytokines play pivotal roles in NK cell activation, proliferation, and effector function:

- Interleukin-2 (IL-2): Promotes NK cell proliferation, enhances cytotoxicity, and induces interferon-gamma (IFN-γ) production. IL-2 therapy has been explored clinically to boost NK cell-mediated anti-tumor immunity.
- Interleukin-12 (IL-12): A potent NK cell activator produced by dendritic cells and macrophages, IL-12 enhances NK cell cytotoxicity and stimulates robust IFN-γ secretion, which further activates macrophages and promotes Th1-type adaptive immune responses.
- Interleukin-15 (IL-15): Critical for NK cell development, survival, and homeostasis, IL-15 promotes NK cell expansion and maintains their functional competence in the tumor microenvironment.

However, in pancreatic cancer, NK cell function is frequently compromised due to the immunosuppressive tumor microenvironment, characterized by elevated levels of TGF-β, prostaglandin E2 (PGE2), and adenosine, all of which directly inhibit NK cell activation and cytotoxicity.

Dendritic Cells: Professional Antigen Presenters

Dendritic cells (DCs) serve as critical bridges between innate and adaptive immunity, functioning as professional antigen-presenting cells that capture, process, and present tumor-associated antigens to T cells. Through

expression of MHC class I and class II molecules, along with co-stimulatory molecules such as CD80, CD86, and CD40, mature DCs are uniquely capable of initiating robust T cell-mediated anti-tumor immune responses.

MHC Class I-Mediated Antigen Presentation

Dendritic cells process intracellular antigens through the proteasome pathway and present peptide fragments on MHC class I molecules to CD8+ cytotoxic T lymphocytes (CTLs). In the context of cancer, DCs can acquire tumor antigens through direct uptake of apoptotic or necrotic tumor cells—a process termed cross-presentation—enabling them to activate tumor-specific CD8+ T cells even without being directly infected or transformed.

Effective cross-presentation is essential for generating cytotoxic T cell responses against tumors, as most tumor antigens are not expressed by DCs themselves. However, in pancreatic cancer, DC function is often impaired due to tumor-derived factors such as VEGF, IL-10, and TGF-β, which inhibit DC maturation, migration to lymph nodes, and antigen-presenting capacity.

Immunosuppressive Impact on Dendritic Cell Function

The pancreatic tumor microenvironment actively suppresses DC maturation and function through multiple mechanisms:

- Impaired maturation: Tumor-derived factors prevent DCs from upregulating co-stimulatory molecules and pro-inflammatory cytokines, resulting in immature DCs that fail to effectively activate T cells.
- Tolerogenic phenotype: Instead of activating effector T cells, dysfunctional DCs may induce T cell tolerance or promote regulatory T cell expansion, further suppressing anti-tumor immunity.
- Reduced migration: Tumor-induced alterations in chemokine gradients impair DC migration to tumor-draining lymph nodes, limiting the initiation of adaptive immune responses.

Strategies to restore DC function—including DC vaccination, use of toll-like receptor (TLR) agonists to promote DC maturation, and blockade of immunosuppressive cytokines—represent promising approaches to enhance anti-tumor immunity in pancreatic cancer.

Neutrophils: Context-Dependent Regulators of Tumor Progression

Neutrophils, the most abundant circulating leukocytes, are increasingly recognized as important modulators of tumor immunity. Similar to macrophages, neutrophils exhibit functional plasticity and can adopt either anti-tumor (N1) or pro-tumor (N2) phenotypes depending on signals within the tumor microenvironment.

N1 Neutrophils: Anti-Tumor Effectors

N1 neutrophils are characterized by immunostimulatory and cytotoxic activity. These cells produce reactive oxygen species (ROS), nitric oxide (NO), and pro-inflammatory cytokines such as TNF-α and IL-12, contributing to direct tumor cell killing and activation of other immune effectors. N1 neutrophils can also enhance T cell responses through antigen presentation and co-stimulatory molecule expression.

Furthermore, N1 neutrophils can release neutrophil extracellular traps (NETs) that physically entrap tumor cells and limit metastatic dissemination. The anti-tumor phenotype is typically induced by type I interferons and TGF-β blockade.

N2 Neutrophils: Pro-Tumor Facilitators

Conversely, N2 neutrophils, which predominate in established pancreatic tumors, promote tumor growth, angiogenesis, and metastasis. These cells are induced by TGF-β and produce immunosuppressive mediators including arginase-1, which depletes arginine and suppresses T cell function, similar to MDSCs.

N2 neutrophils also secrete matrix metalloproteinases (MMP-9) that remodel the extracellular matrix, facilitating tumor invasion and angiogenesis. Additionally, they release VEGF and other pro-angiogenic factors that support tumor vascularization. The neutrophil-to-lymphocyte ratio (NLR) in peripheral blood has emerged as a prognostic biomarker in pancreatic cancer, with elevated NLR correlating with poor outcomes, likely reflecting N2 neutrophil predominance.

T Cell Activation and Protein Synthesis

T cell activation represents a crucial endpoint in the anti-tumor immune cascade. Following antigen recognition via the T cell receptor (TCR) and co-stimulatory signal engagement (such as CD28 binding to CD80/CD86), T cells undergo clonal expansion and differentiate into effector cells capable of producing cytotoxic molecules and inflammatory cytokines.

Activated T cells dramatically upregulate protein synthesis to support their proliferative burst and effector functions. This metabolic reprogramming involves increased ribosomal biogenesis, enhanced mRNA translation, and elevated production of cytokines (such as IFN-γ, TNF-α, and IL-2), cytotoxic granules (perforin and granzymes), and proliferation-associated proteins.

However, in the immunosuppressive pancreatic tumor microenvironment, T cell activation is frequently inhibited by checkpoint molecules (PD-1/PD-L1, CTLA-4), nutrient depletion (arginine, tryptophan), and inhibitory cytokines

(TGF-β, IL-10), limiting the effectiveness of T cell-mediated anti-tumor immunity.

Therapeutic Implications

Understanding the complex interplay between diverse immune cell populations in the pancreatic tumor microenvironment has profound implications for developing effective immunotherapeutic strategies. Emerging therapeutic approaches aim to:

- Reprogram immunosuppressive cells: Strategies targeting macrophage polarization (e.g., CSF-1R inhibitors to deplete M2 macrophages) or MDSC differentiation hold promise for reducing immunosuppression.
- Enhance NK cell activity: Combination approaches using IL-15 agonists, checkpoint blockade (anti-NKG2A, anti-KIR), or NK cell-engaging bispecific antibodies may overcome NK cell dysfunction.
- Restore dendritic cell function: DC vaccines, TLR agonists (such as poly-ICLC), and combination with checkpoint inhibitors may improve DC-mediated T cell priming.
- Modulate neutrophil phenotype: Blockade of TGF-β or CXCR2 to prevent N2 neutrophil recruitment represents an area of active investigation.
- Combine immunotherapy with conventional treatments: Integration of immune checkpoint inhibitors with chemotherapy, radiation, or targeted therapies may synergistically enhance anti-tumor immunity by inducing immunogenic cell death and altering the tumor microenvironment.

Conclusion

The immune landscape of pancreatic cancer is characterized by extraordinary complexity, featuring multiple immune cell populations that engage in intricate cross-talk and exhibit remarkable functional plasticity. While the tumor microenvironment is profoundly immunosuppressive, dominated by M2 macrophages, MDSCs, regulatory T cells, and N2 neutrophils, it also contains anti-tumor effectors including M1 macrophages, NK cells, dendritic cells, and cytotoxic T lymphocytes. The therapeutic challenge lies in tipping this balance toward effective anti-tumor immunity through strategic modulation of immune cell phenotypes, blockade of immunosuppressive pathways, and enhancement of effector cell function. As our understanding of these immunological dynamics deepens, rational combination immunotherapy strategies hold promise for improving outcomes in this devastating disease.

Reference

*Thankachan, S.V.; Jayaraman, V.; Datta, L.; Apthi, S.; Zaman, B.F.; Gurunathan, R.; Suresh, A.; Chandrakesan, P.; Vinayagam, R.; Kang, S.G.; et al. Tumor Microenvironment: Recent Advances in Immunotherapies of Pancreatic Cancer. Medicina 2025, **61**, 1776.*